The Expert Weighs In: Pharmacology for the Treatment of Obesity: Is There A Place for Rimonabant?: Interview with Jean-Pierre Després, Ph.D., FAHA, Director of Research Quebec Heart Institute, Hôpital Laval Research Center, Quebec, Canada

摘要

Jean-Pierre Després is Director of Research atnthe Quebec Heart Institute located at HôpitalnLaval in Quebec City and has 25 years experiencenas a researcher in the field of obesity, with anfocus on visceral obesity and its relationship withnatherogenic dyslipidemias, insulin resistance and featuresnof what we now call the “metabolic syndrome.”nDuring this period, he has published 450 papers innpeer-reviewed journals. Dr. Després was the PrincipalnInvestigator on the RIO-Lipids (Rimonabant innObesity-Lipids) trial, the findings from which werenpublished in the New England Journal of Medicine.nRecently, Robert Ross, PhD, Director of the CORE atnQueen’s University in Kingston, Canada, spoke with Dr.nDesprés about the current situation with the CB1 antagonistnRimonabant.